GSK-2849466 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK). This experimental compound reached Phase I clinical trials for the treatment of cachexia and heart failure. However, as of February 2014, GSK discontinued the development of GSK-2849466 for both indications after completing Phase I studies.
References